Robeco Institutional Asset Management B.V. Sells 3,099 Shares of Humana Inc. (NYSE:HUM)

Robeco Institutional Asset Management B.V. decreased its position in Humana Inc. (NYSE:HUM - Free Report) by 27.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,063 shares of the insurance provider's stock after selling 3,099 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Humana were worth $2,046,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. International Assets Investment Management LLC boosted its stake in shares of Humana by 261,025.1% in the 3rd quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider's stock valued at $2,340,660,000 after purchasing an additional 738,701 shares in the last quarter. FMR LLC grew its stake in shares of Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider's stock valued at $1,073,387,000 after buying an additional 643,291 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of Humana by 55.6% in the third quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider's stock worth $190,145,000 after buying an additional 214,535 shares during the period. Pzena Investment Management LLC lifted its stake in shares of Humana by 8.1% in the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider's stock valued at $793,830,000 after acquiring an additional 187,903 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC purchased a new stake in Humana during the 3rd quarter valued at about $50,102,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HUM. Wells Fargo & Company decreased their price target on Humana from $387.00 to $290.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. TD Cowen lifted their target price on shares of Humana from $261.00 to $268.00 and gave the stock a "hold" rating in a research note on Monday, November 4th. Sanford C. Bernstein raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $308.00 price target for the company in a research report on Tuesday, October 8th. Truist Financial boosted their price objective on shares of Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research report on Monday, January 6th. Finally, Barclays increased their target price on shares of Humana from $253.00 to $255.00 and gave the stock an "equal weight" rating in a report on Wednesday, January 22nd. Nineteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $297.68.

Humana Stock Down 1.7 %

Shares of HUM traded down $5.02 during mid-day trading on Wednesday, reaching $290.52. The company had a trading volume of 1,102,501 shares, compared to its average volume of 1,506,460. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The company has a market capitalization of $34.98 billion, a price-to-earnings ratio of 25.73, a price-to-earnings-growth ratio of 2.21 and a beta of 0.56. The firm has a 50-day moving average price of $275.13 and a 200 day moving average price of $299.72. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the firm's stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.29% of the stock is owned by company insiders.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.